Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment (Q37873950)

24 August 2017

1 reference

title

Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment (English)

1 reference

24 August 2017

0 references

organ transplantation

1 reference

1 reference

Barry Kahan

1

1 reference

PubMed ID

21557712

24 August 2017

language of work or name

English

0 references

publication date

11 May 2011

1 reference

Expert Opinion on Drug Safety

24 August 2017

1 reference

24 August 2017

10

1 reference

24 August 2017

5

1 reference

24 August 2017

727-749

1 reference

The mTOR signaling network: insights from its role during embryonic development

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

A signaling pathway to translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

21 January 2018

mTOR-what does it do?

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Hypothesis: epithelial-to-mesenchymal transition is a common cause of chronic allograft failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

The multifunctional role of mTOR in innate immunity: implications for transplant immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Median effect analysis of efficacy versus adverse effects of immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Molecular correlates of renal function in kidney transplant biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Evidence that fibroblasts derive from epithelium during tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus attenuates the expression of metalloproteinase-2 and -9 and inhibits intimal hyperplasia following balloon angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Aortic stiffness, kidney disease, and renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Ar

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Higher incidence and serum levels of minor cardiac biomarker elevation in sirolimus-eluting stent (Cypher) than bare metal stent implantations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Anemia after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Anemia after kidney transplantation is not completely explained by reduced kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Possible mechanism by which rapamycin increases cyclosporine nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Optimizing early de novo immunosuppression with sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus improves renal function in cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Proteinuria after renal transplantation affects not only graft survival but also patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Proteinuria following a switch from calcineurin inhibitors to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Oral ulcers in kidney allograft recipients treated with sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus inhibits oxidative burst activity in transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Patient survival after renal transplantation: IV. Impact of post-transplant diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

The metabolic effects of cyclosporin and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait-Listed and Transplanted Renal Allograft Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Mammalian target of rapamycin and diabetes: what does the current evidence tell us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin Has a Deleterious Effect on MIN-6 Cells and Rat and Human Islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus-associated infertility: case report and literature review of possible mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Rapamycin-induced oligospermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus impairs gonadal function in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Clinical pharmacokinetics of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.579898

10.1517/14740338.2011.579898

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21557712